None of the currently available Pataday formulas are preservative-free. Every over-the-counter Pataday product, whether it is the Twice Daily Relief (0.1%), Once Daily Relief (0.2%), or Once Daily Extra Strength (0.7%), contains benzalkonium chloride (BAK) as a preservative. This matters more than you might expect, because BAK is one of the more controversial ingredients in eye care, and understanding which Pataday formula you are using and how often you instill it can help you minimize any downsides.
What Each Pataday Formula Contains
Pataday’s active ingredient across all three strengths is olopatadine hydrochloride, a dual-action compound that works both as a mast cell stabilizer and as a histamine receptor blocker. That dual mechanism is part of what makes it effective for allergic conjunctivitis: it reduces the release of histamine and other inflammatory chemicals from mast cells in the eye, while also blocking histamine receptors on surrounding tissue so that whatever histamine does get released has less effect.1PubMed. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell The three formulas differ in concentration and dosing frequency, but all share benzalkonium chloride as an inactive ingredient.
Two of the three strengths became available without a prescription after a regulatory switch. Olopatadine 0.1%, marketed as Pataday Twice Daily Relief, and olopatadine 0.2%, marketed as Pataday Once Daily Relief, were both moved from prescription-only to over-the-counter status.2AJN, American Journal of Nursing. Three Prescription Drugs are Now Available Over the Counter The highest concentration, 0.7% (sold as Pataday Once Daily Extra Strength, formerly the prescription product Pazeo), later joined the OTC lineup as well. All three bottles are multi-dose containers, and BAK is the preservative that keeps bacteria from growing in the solution between uses.
How the Three Strengths Compare in Practice
The 0.1% formula is instilled twice a day, roughly six to eight hours apart. The 0.2% version was designed to extend the duration of relief so that a single daily drop suffices, with studies confirming itch reduction lasting up to 24 hours.3PubMed Central. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing The 0.7% formula takes that a step further. In pooled clinical trials, the 0.7% concentration outperformed both the vehicle placebo and the 0.2% formula in controlling ocular itch at 24 hours, with a meaningfully higher proportion of patients reporting itch relief.4PubMed Central. Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
From a preservative-exposure standpoint, the practical difference is straightforward: the 0.1% formula delivers BAK to your eye twice daily, while the 0.2% and 0.7% formulas deliver it once. If you are concerned about cumulative preservative exposure but want olopatadine specifically, the once-daily formulas cut your BAK contact in half compared to the twice-daily version.
Why Benzalkonium Chloride Is in Eye Drops at All
BAK is a quaternary ammonium compound that kills bacteria and fungi on contact. It has been the default preservative in ophthalmic products for decades, largely because it is cheap, effective, and compatible with a wide range of active ingredients. When you open a multi-dose eye drop bottle and use it over weeks, you repeatedly expose the tip to your fingers, lashes, and the air. Without a preservative, the solution inside becomes a warm, moist breeding ground for microorganisms. BAK prevents that.
The problem is that BAK is not selective. The same properties that make it lethal to bacteria also damage the cells on your eye’s surface. Laboratory studies show that BAK directly targets mitochondria in human cells, shutting down energy production and oxygen consumption in a dose-dependent way. At the concentrations used in commercial eye drops, BAK can inhibit mitochondrial function by more than 90 percent in exposed cells.5PubMed Central. The Eye Drop Preservative Benzalkonium Chloride Potently Induces Mitochondrial Dysfunction and Preferentially Affects LHON Mutant Cells That is a dramatic number, though it comes from in vitro cell models rather than from measuring what happens on an intact, blinking eye with a tear film diluting the drop. Still, the direction of the finding is concerning enough that the eye care field has been moving toward preservative-free options where possible.
What BAK Actually Does to the Eye’s Surface
The cornea and conjunctiva are covered by a thin layer of epithelial cells that serve as a barrier against infection and irritation. BAK disrupts that barrier. In cell culture studies, even very low concentrations of BAK reduced the ability of corneal epithelial cells to form colonies, while higher concentrations triggered cell contraction, membrane damage, and a roughly four-fold increase in cell death.6PubMed. Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease Separate research found that BAK exposure caused corneal epithelial cells to release inflammatory signaling molecules and undergo programmed cell death, and that this inflammatory response could also affect the trigeminal nerve cells that supply sensation to the cornea.7PubMed. Benzalkonium chloride-induced direct and indirect toxicity on corneal epithelial and trigeminal neuronal cells: proinflammatory and apoptotic responses in vitro
In practical terms, for someone using a single BAK-containing eye drop once a day during allergy season, the real-world impact on the ocular surface is usually minor. The tear film dilutes the preservative quickly, and healthy corneal cells regenerate. The concerns escalate when you are using multiple preserved drops daily or using them for months on end, which is where the cumulative toll starts to resemble a low-grade dry eye pattern.
When Preservative-Free Matters Most
Not everyone needs to worry equally about BAK. Seasonal allergy sufferers who use Pataday for a few weeks each spring are in a very different position from someone using it year-round alongside preserved glaucoma drops and artificial tears. The clinical consensus is that preservative-free formulations matter most for people on long-term therapy requiring multiple daily instillations, especially when there is an existing ocular surface problem like dry eye disease or a corneal condition that makes the surface more vulnerable to chemical stress.8PubMed. Topical preservative-free ophthalmic treatments: an unmet clinical need
People who fall into higher-risk categories include:
- Contact lens wearers: BAK can be absorbed by soft contact lenses and then slowly released against the cornea, extending exposure time well beyond the initial drop. Most preserved eye drops, Pataday included, carry instructions to remove contacts before instilling and wait at least ten minutes before reinserting.
- Glaucoma patients: Many glaucoma medications already contain BAK, and adding a preserved allergy drop on top multiplies the daily preservative dose. This group stands to benefit most from preservative-free alternatives wherever they exist.
- People with dry eye: If your eyes are already inflamed, your tear film is already compromised, and your corneal surface is already fragile, BAK makes everything worse. Using a preserved allergy drop to treat itch while simultaneously worsening the underlying surface is counterproductive.
- Long-term users: Someone who uses Pataday year-round for perennial allergies accumulates far more BAK exposure than someone who uses it for six weeks in pollen season.
If you do not fall into any of those categories, the BAK in a once-daily Pataday drop is unlikely to cause noticeable harm to your eyes. But if you are stacking multiple drops or using them chronically, it is worth asking your eye doctor whether a preservative-free antihistamine option exists for your situation.
Why No Preservative-Free Pataday Exists Yet
You might wonder why the manufacturer has not simply released a BAK-free version. Part of the answer is economic and regulatory: reformulating a product without its preservative means either switching to a different preservative system, redesigning the bottle to be single-use (individual vials rather than a multi-dose bottle), or engineering a multi-dose container with a built-in antimicrobial barrier. All of these options raise manufacturing costs and require new regulatory filings.
Some eye drop categories have moved faster toward preservative-free delivery than others. Artificial tears are widely available in single-use vials. Certain glaucoma medications now come in multi-dose bottles with filters or one-way valves that prevent contamination without needing a chemical preservative. Research has even explored novel filter tips that can selectively remove BAK from a multi-dose bottle as the drop passes through, stripping out nearly 100 percent of the preservative while leaving the active drug largely intact.9PubMed. Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations Technologies like that could theoretically be applied to any BAK-containing eye drop, but as of now they have not made it into mainstream allergy eye drops.
There are preservative-free antihistamine eye drops on the market from other brands, though they use different active ingredients. If avoiding preservatives is a priority for you, those alternatives exist, but you would be switching away from olopatadine’s specific dual mechanism.
Comfort and Tolerability of Olopatadine Itself
Setting aside the preservative question, olopatadine has a notably good comfort profile compared to some other ophthalmic antihistamines. Head-to-head comparisons in conjunctival allergen challenge tests found that olopatadine 0.1% caused less discomfort on instillation than levocabastine, and unlike several competing antihistamines (ketotifen, epinastine, azelastine), olopatadine did not cause observable cell membrane disruption in conjunctival cells in laboratory testing.10Dove Press (Clinical Ophthalmology). Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops That lack of cell membrane disruption may explain why fewer patients report stinging or burning with Pataday than with some alternatives.
This is an important nuance for people who assume their eye irritation from Pataday is caused by the drug itself. In many cases, the stinging or dryness that develops after weeks of use may be driven more by the BAK than by the olopatadine. If you find that Pataday relieves your itch but leaves your eyes feeling irritated or dry over time, the preservative is a more likely culprit than the active ingredient.
Using Pataday in Children
Pataday is commonly used in children, and the safety data for the 0.2% once-daily formula in pediatric patients is reassuring. A study evaluating 126 children and adolescents aged 3 to 17 found no clinically meaningful changes in visual acuity, eye pressure, or any structural measure on slit-lamp or fundus exams after six weeks of daily use. All reported adverse events were mild or moderate.11PubMed. Safety and tolerability of olopatadine 0.2% in children and adolescents
That said, the BAK question is worth considering for kids too. Children with allergic conjunctivitis often also have allergic rhinitis and may be using multiple medications. Some children rub their eyes aggressively during allergy flares, which can compromise the corneal surface and make it more susceptible to preservative-related irritation. For a child using Pataday for a defined allergy season, the BAK exposure is manageable. For a child who ends up on year-round therapy, a conversation with a pediatric ophthalmologist or allergist about preservative-free alternatives is reasonable.
Practical Tips for Reducing Preservative Exposure
If you want the benefits of Pataday but are concerned about BAK, a few strategies can help minimize the impact without switching medications entirely.
- Choose once-daily dosing: The 0.2% or 0.7% formulas mean one BAK exposure per day instead of two.
- Use preservative-free artificial tears: Instilling a preservative-free lubricant drop about 10 to 15 minutes after your Pataday dose can help dilute residual BAK on the ocular surface and support the tear film.
- Limit the season: Use Pataday during your worst allergy weeks rather than preemptively starting weeks before symptoms appear. Shorter courses mean less total BAK exposure.
- Avoid stacking preserved drops: If you are already on a preserved glaucoma drop or a preserved artificial tear, adding preserved Pataday on top triples your BAK load. Talk to your doctor about switching one of those other drops to a preservative-free version.
None of these steps eliminate BAK from your Pataday drop, but they reduce cumulative exposure and support the eye’s ability to recover between doses. For most seasonal allergy sufferers, these measures are more than sufficient to keep the ocular surface healthy while still getting effective itch relief.
How to Read the Label
If you pick up a box of Pataday at the pharmacy and want to check for yourself, look at the “inactive ingredients” list on the Drug Facts panel. Benzalkonium chloride will be listed there. It will not appear under “active ingredients” because it is not the therapeutic component; it is there solely to preserve the solution. Some consumers confuse the absence of BAK from the active ingredient list with the product being preservative-free, which is how the misconception that Pataday is BAK-free sometimes spreads online.
Also watch for store-brand or generic olopatadine drops. These generics contain the same active ingredient and, in most cases, the same preservative. A generic label that says “Compare to Pataday” is not an indication that the formulation is preservative-free; it just means the active ingredient matches. If a truly preservative-free olopatadine product ever reaches the market, it will be prominently labeled as such, because “preservative-free” is a significant selling point that manufacturers do not keep quiet about.